Fabrication, characterization, and in vitro biological evaluation of glycyrrhetinic acid ligand-functionalized proliposomes encapsulated docetaxel for treatment of hepatocellular carcinoma

IF 4.9 2区 化学 Q2 CHEMISTRY, PHYSICAL
Yuan Lin , Chuangnan Li , Kaijie Cen , Jucai Xu , Jing Chen
{"title":"Fabrication, characterization, and in vitro biological evaluation of glycyrrhetinic acid ligand-functionalized proliposomes encapsulated docetaxel for treatment of hepatocellular carcinoma","authors":"Yuan Lin ,&nbsp;Chuangnan Li ,&nbsp;Kaijie Cen ,&nbsp;Jucai Xu ,&nbsp;Jing Chen","doi":"10.1016/j.colsurfa.2024.135802","DOIUrl":null,"url":null,"abstract":"<div><div>Docetaxel (DTX) is a chemotherapeutic drug extracted from the needles of Taxus baccata with a broad anticancer spectrum that has been widely used for the treatment of various cancers. However, its high hydrophobicity and poor solubility results in low bioavailability that restricted clinical application. To circumvent these challenges, the present investigation was performed to develop DTX proliposomes mediated glycyrrhetinic acid ligand (glycyrrhetinic acid - diaminododecane - cholestrol, GADC) for the treatment of hepatocellular carcinoma. The optimal parameters of liposome formulation were egg phosphatidylcholine/cholesterol mass ratio of 9:1, the ratio of DTX to lipid substance within 1/10, the percent of GADC ligand (8 %), hydration time of 30 min and homogenization time of 10 min. To protect DTX liposomes from external environment during their storage, DTX proliposomes mediated GADC (GADC-DTX-PL), three optimum processing variables, lyoprotectants of sucrose and mannitol, the sucrose/mannitol ratio of 1:1, and the lyoprotectant/egg phosphatidylcholine of 8:1, were obtained after investigation. Under the optimum lyophilization conditions, GADC-DTX-PL was prepared and reconstituted proliposomes were determined to evaluate its physicochemical characterizations. These proliposomes showed that GADC-DTX-PL were spherical particles with an average size of 214.88 ± 11.00 nm, PDI value of 0.23 ± 0.00, zeta potential of –20.04 ±4.94 mV, encapsulation efficiency of 80.58 ± 0.91 %, and drug loading of 7.39 %. In addition, encapsulation of DTX in proliposomal formulation resulted in stable and slow drug release. Furthermore, <em>in vitro</em> bioactivity was evaluated, cytotoxicity effect and apoptosis efficiency of GADC-DTX-PL by HepG2 cells was significantly higher than that of DTX proliposomes without GADC. In the cell cycle assay, the results confirmed that the effect of GADC-DTX-PL regarding the initiation of apoptosis is accompanied with adjustment in the cell cycle progress via generating G2/M arrest. This potential of this novel approach for delivery DTX to hepatocellular cells lies in the ability to combine a targeted ligand of GADC and proliposomes simultaneously. Such formulation of GADC-DTX-PL enhances the selectivity of DTX delivery to hepatocellular cells, thereby improving the efficacy of chemotherapy.</div></div>","PeriodicalId":278,"journal":{"name":"Colloids and Surfaces A: Physicochemical and Engineering Aspects","volume":"707 ","pages":"Article 135802"},"PeriodicalIF":4.9000,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Colloids and Surfaces A: Physicochemical and Engineering Aspects","FirstCategoryId":"92","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0927775724026669","RegionNum":2,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, PHYSICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Docetaxel (DTX) is a chemotherapeutic drug extracted from the needles of Taxus baccata with a broad anticancer spectrum that has been widely used for the treatment of various cancers. However, its high hydrophobicity and poor solubility results in low bioavailability that restricted clinical application. To circumvent these challenges, the present investigation was performed to develop DTX proliposomes mediated glycyrrhetinic acid ligand (glycyrrhetinic acid - diaminododecane - cholestrol, GADC) for the treatment of hepatocellular carcinoma. The optimal parameters of liposome formulation were egg phosphatidylcholine/cholesterol mass ratio of 9:1, the ratio of DTX to lipid substance within 1/10, the percent of GADC ligand (8 %), hydration time of 30 min and homogenization time of 10 min. To protect DTX liposomes from external environment during their storage, DTX proliposomes mediated GADC (GADC-DTX-PL), three optimum processing variables, lyoprotectants of sucrose and mannitol, the sucrose/mannitol ratio of 1:1, and the lyoprotectant/egg phosphatidylcholine of 8:1, were obtained after investigation. Under the optimum lyophilization conditions, GADC-DTX-PL was prepared and reconstituted proliposomes were determined to evaluate its physicochemical characterizations. These proliposomes showed that GADC-DTX-PL were spherical particles with an average size of 214.88 ± 11.00 nm, PDI value of 0.23 ± 0.00, zeta potential of –20.04 ±4.94 mV, encapsulation efficiency of 80.58 ± 0.91 %, and drug loading of 7.39 %. In addition, encapsulation of DTX in proliposomal formulation resulted in stable and slow drug release. Furthermore, in vitro bioactivity was evaluated, cytotoxicity effect and apoptosis efficiency of GADC-DTX-PL by HepG2 cells was significantly higher than that of DTX proliposomes without GADC. In the cell cycle assay, the results confirmed that the effect of GADC-DTX-PL regarding the initiation of apoptosis is accompanied with adjustment in the cell cycle progress via generating G2/M arrest. This potential of this novel approach for delivery DTX to hepatocellular cells lies in the ability to combine a targeted ligand of GADC and proliposomes simultaneously. Such formulation of GADC-DTX-PL enhances the selectivity of DTX delivery to hepatocellular cells, thereby improving the efficacy of chemotherapy.
多西紫杉醇包封的甘草次酸配体功能化原脂质体治疗肝癌的制备、表征和体外生物学评价
多西紫杉醇(Docetaxel, DTX)是从红豆杉(Taxus baccata)针叶中提取的一种具有广泛抗癌谱的化疗药物,已被广泛用于各种癌症的治疗。但其高疏水性和低溶解度导致生物利用度低,限制了临床应用。为了克服这些挑战,本研究旨在开发DTX原脂质体介导的甘草次酸配体(glycyrrhetinic acid - diaminododecane - cholesterol, GADC)用于治疗肝细胞癌。脂质体的最佳处方参数为:鸡蛋磷脂酰胆碱/胆固醇质量比为9:1,DTX与脂质质量比在1/10以内,GADC配体的比例为8 %,水化时间30 min,均质时间10 min。为了保护DTX脂质体在贮藏过程中不受外界环境的影响,研究了DTX原脂质体介导GADC (GADC-DTX- pl)、蔗糖和甘露醇的溶解保护剂、蔗糖/甘露醇的比例为1:1、溶解保护剂/蛋磷脂酰胆碱的比例为8:1这三个最佳工艺参数。在最佳冻干条件下,制备了GADC-DTX-PL,并测定了重组的原脂质体的理化性质。结果表明,gadc - ddx - pl为球形颗粒,平均粒径为214.88±11.00 nm, PDI值为0.23±0.00,zeta电位为-20.04±4.94 mV,包封效率为80.58±0.91%,载药量为7.39 %。此外,DTX包封在原脂质体制剂中,使药物释放稳定、缓慢。体外生物活性评价表明,GADC-DTX- pl对HepG2细胞的细胞毒作用和凋亡效率显著高于未加GADC的DTX原脂质体。在细胞周期实验中,结果证实了GADC-DTX-PL对细胞凋亡起始的影响伴随着通过产生G2/M阻滞来调节细胞周期进程。这种将DTX输送到肝细胞的新方法的潜力在于能够同时结合GADC和原脂质体的靶向配体。这样的GADC-DTX-PL配方增强了DTX递送到肝细胞的选择性,从而提高了化疗的疗效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.70
自引率
9.60%
发文量
2421
审稿时长
56 days
期刊介绍: Colloids and Surfaces A: Physicochemical and Engineering Aspects is an international journal devoted to the science underlying applications of colloids and interfacial phenomena. The journal aims at publishing high quality research papers featuring new materials or new insights into the role of colloid and interface science in (for example) food, energy, minerals processing, pharmaceuticals or the environment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信